Second Sight Medical Products Inc. (EYES)

Name: Second Sight Medical Products Inc. (EYES) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Second Sight Medical Products Inc. (EYES)

Stock Card

$28.73

$24.59 (594.01%)

As on 04-Sep-2026 15:31EDT

Market cap

$54 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

0.9

Div. Yield

0 %

Second Sight Medical Products (EYES) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 28.73 High: 28.87

52 Week Range

Low: 28.73 High: 28.87

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-9 Mln
ROE

-0.1 %
ROCE

-- %
Industry P/E

46.09
EV/EBITDA

0.2
Debt to Equity

0
Book Value

$--
EPS

$--
Face value

--
Shares outstanding

13,136,400

10 Years Aggregate

CFO

$-202.86 Mln

EBITDA

$-224.18 Mln

Net Profit

$-239.74 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Second Sight Medical Products (EYES)	--	--	--	--	--	20.7	-10.0
BSE Sensex^*	-10.7	-3.7	1.8	-6.4	4.5	5.3	10.1
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 04-Sep-2026 | *As on 08-Sep-2026 | #As on 26-Oct-2023

Company	2021	2020	2019	2018	2017	2016	2015
Second Sight Medical Products (EYES)	-12.8	-68.5	-16.2	-53.4	-3.0	-66.6	-42.6
S&P Small-Cap 600	25.3	9.6	20.9	-9.7	11.7	24.7	-3.4
BSE Sensex	22.0	15.8	14.4	5.9	27.9	1.9	-5.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Second Sight Medical Products (EYES)

The fund is an exchange-traded fund (ETF) that seeks to meet its objective by having Corgi Strategies, LLC (the adviser) actively manage the fund and, under ordinary market conditions, invest at least 80% of its net assets (plus any borrowings for... investment purposes) in a portfolio of companies materially involved in the development and deployment of technologies that collect, process, secure, analyze, and operationalize data for monitoring, risk management, security, compliance, and operational visibility across public and private environments. It is non-diversified. Read more

Acting Chief Exec. Officer

Mr. Scott Dunbar
Acting Chief Exec. Officer

Mr. Scott Dunbar
Headquarters

Sylmar, CA
Website

https://www.secondsight.com

FAQs for Second Sight Medical Products (EYES)

What is the current share price of Second Sight Medical Products Inc (EYES) Today?

The share price of Second Sight Medical Products Inc (EYES) is $28.73 (NASDAQ) as of 04-Sep-2026 15:31 EDT. Second Sight Medical Products Inc (EYES) has given a return of --% in the last 1 years.

What is the current PB & PE ratio of Second Sight Medical Products Inc (EYES)?

Since, TTM earnings of Second Sight Medical Products Inc (EYES) is negative, P/E ratio is not available.
The P/B ratio of Second Sight Medical Products Inc (EYES) is 0.86 times as on 30-Aug-2022, a 77 discount to its peers’ median range of 3.78 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2021	--	--
2020	--	--
2019	--	--
2018	--	--
2017	--	--

What is the 52 Week High and Low of Second Sight Medical Products Inc (EYES)?

The 52-week high and low of Second Sight Medical Products Inc (EYES) are Rs 28.87 and Rs 28.73 as of 08-Sep-2026.

What is the market cap of Second Sight Medical Products Inc (EYES)?

Second Sight Medical Products Inc (EYES) has a market capitalisation of $ 54 Mln as on 30-Aug-2022. As per SEBI classification, it is a Small Cap company.

Should I invest in Second Sight Medical Products Inc (EYES)?

Before investing in Second Sight Medical Products Inc (EYES), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.